Not Applicable PM-16 Inpatient Early Cardiac Troponin Measurement (Within 6 Hours of Arrival) This measure seeks to implement Class I (Level of Evidence A) recommendations in the 2014 AHA/ACC NSTE-ACS guideline11 to measure serial cardiac troponin levels (at presentation and 3 to 6 h after symptom onset in all patients). Not Applicable PM-17 Inpatient Participation in Regional or National Acute Myocardial Infarction Registry This measure seeks to implement Class I (Level of Evidence B) and Class IIa (Level of Evidence B) recommendations in the 2013 STEMI12 AHA/ACC NSTE-ACS guidelines,11 respectively. The writing group felt that participation in a regional or national AMI registry will help track and assess the outcomes, complications, and quality of care for patients with AMI, and is supported by evidence. Not Applicable QM-1 Inpatient Risk Score Stratification for NSTEMI Patients This measure seeks to implement a Class I (Level of Evidence A) recommendation in the 2014 guideline that risk scores should be used to assess prognosis in patients with NSTE-ACS. The writing committee realizes the importance of this measure to dictate the appropriate strategy (invasive versus ischemic- guided) and the timing of the strategy (early versus late invasive) in patients with NSTEMI. The writing committee felt it was best to keep this as a quality measure because of issues related to the measure feasibility. Most registries do not include risk scores, and most risk scores (eg, GRACE, TIMI, PURSUIT) are difficult to compute retrospectively from their respective components, and are likely to cause a significant abstraction burden. QM-2 Inpatient Early Invasive Strategy (Within 24 Hours) in High-Risk NSTEMI Patients This measure seeks to implement a Class I (Level of Evidence A) recommendation in the 2014 AHA/ ACC NSTE-ACS guideline11 that an early invasive strategy should be performed in initially stabilized high-risk patients with NSTE-ACS. 